The project PHOENIX – NCBiR aims to measure heart’s regenerative potential with use of autological mesenchymal stem cells (MSC) given to patients with advanced heart failure directly to the cardiac muscle or through stem cell-enriched scaffold. The project is dedicated to patients with acute and symptomatic ischaemic heart disease who used up all the assets of modern pharmacological and surgical treatment, i.e. the so called “no-option patients”.
The stem cell-enriched scaffold (CERES) developed and tested in terms of the project PHOENIX is bound to ultimately become a complete product stimulating the revascularisation of ischaemic parts of the cardiac muscle and recovering its contractibility. Three unique clinical trials conducted in terms of the project has contributed to acquiring knowledge about the therapeutical and commercial potential of MSC and CERES. Hence, the project aims to grant broad population of patients access to modern and affordable treatment increasing lifespan and improving the quality of life

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    I consent to the processing of my personal data by Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o., 10C M. Curie-Skłodowskiej St., 41-800 Zabrze, KRS:0000396540, NIP:6482761515, Regon:242742607, as Data Controler in order to receive a response. I can withdraw my consent by submitting a statement to: The Data Controler has notified me that this consent does not affect the legality of the processing carried out on the basis of consent before its withdrawal.

    The information clause on the details of the processing is available here.

    Supporting partners: